HARP - Gunggung utang perusahaan Harpoon Therapeutics, Inc.

The visual price representation for Harpoon Therapeutics (HARP) available on the page demonstrates the asset dynamics of the company, which is developing an innovative line of drugs against solid tumors as part of Merck. The business relies on unique TriTAC trispecific antibodies that bind albumin, T-cells, and the target, ensuring a long-lasting effect. Meanwhile, management is focused on conducting precise clinical tests. The individual debt metric is 0.07.

This indicator assesses debt sustainability by aggregating all short-term and long-term credit obligations, including bond loans. By analyzing the total amount of liabilities, an investor can determine the actual level of financial leverage, which for Harpoon Therapeutics (HARP) is offset by protection against acquisition by a pharma behemoth and the ownership of unique antibody patents that transform FDA regulatory barriers into a long-term competitive advantage.